Earnings
Incyte Cancels Ovarian Cancer Trial Planned For The Fourth Quarter Of 2026
The drugmaker attributed the decision to research priorities and expects its financial guidance and long-term outlook to be unaffected.
Incyte (INCY) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
The drugmaker attributed the decision to research priorities and expects its financial guidance and long-term outlook to be unaffected.
Earnings
The $1.23 billion Vega write-off was not deductible, leaving Incyte with a $784.8 million third-quarter net loss despite 14% revenue growth.
SEC Filings
A one-time $1.23 billion Vega charge swamped profit, while Opzelura and cancer-drug sales grew and guidance rose.